The odds of RFK Jr. implementing a ban on TV drug ads are slim, says our guest this week, BranchLab’s Josh Walsh. Still, pharma advertisers could face other regulatory changes over the next four years. Plus: We break down Forrester’s picks for the top 10 SSPs.
